Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903)

ConclusionsAlthough the primary endpoint was not met, S-1/mitomycin-C chemoradiotherapy had an acceptable toxicity profile and favorable 3-year survival and could be a treatment option for locally advanced SCCA.Clinical trial informationjRCTs031180002.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research